Zydus Lifesciences Ltd.

Zydus Lifesciences has received the Establishment Inspection Report (EIR) from the USFDA for a GMP follow-up inspection conducted at its injectable facility located at Jarod, Vadodara from August 25 to September 05, 2025 and classifying the facility as Voluntary Action Indicated (VAI). This inspection was conducted following the warning letter issued on August 29, 2024 by the USFDA.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.